In a phase II clinical study, patients with histologically confirmed advanced prostate cancer who had no symptoms of metastatic disease were treated with troglitazone (800 mg per day orally) and showed extended stabilization of prostate-specific antigen (PSA) concentrations, indicating disease stabilization. This evidence concerns the gene KLK3 and prostate carcinoma.